| |||||||||||||||||||||||||||||||||||||
More than 150 years ago in London, an astute physician, John Snow, described the mode of transmission of cholera (nearly 30 years before Robert Koch discovered the causative agent, Vibrio cholerae; see photo and slide show), and a visionary engineer, Joseph Bazalgette, established an effective means of preventing it: the provision of municipal sanitation. Cholera is thus one of the first infections whose mode of transmission was understood and for which effective prevention measures, collectively referred to as "the sanitary revolution," were developed and implemented. Because of these early observations and interventions, cholera has become vanishingly rare in the United States and other developed countries.
|
Since we understand the transmission, prevention, and treatment of cholera so well, the disease poses little risk to people of means, even in the poorest societies. Treated bottled or running water, soap or hand sanitizer, and private flush toilets are available in every city in the world, though their price is often beyond the reach of the general population. Travelers to countries where cholera is endemic or epidemic may purchase further protection through immunization for a fraction of their plane fare. If infected, people with cash or credit can easily obtain effective therapies, such as ORT and antimicrobial agents.
Unlike the severe acute respiratory syndrome, avian influenza, and other infectious-disease threats that have emerged recently, cholera is easily avoided and easily treated. The failure of the global community to mobilize the resources needed to prevent and to treat cholera among the less fortunate reflects our lack of commitment to equity and social justice. Improving access to safe drinking water, adequate sanitation, and basic health services are among the core Millennium Development Goals agreed to by all United Nations member states.
Epidemic cholera represents a fundamental failure of governance, and bold and visionary leadership is required if we are to attack its root causes. Such leadership has been demonstrated in other contexts in Africa. For example, President Yoweri Museveni of Uganda began to change public attitudes toward the human immunodeficiency virus and succeeded in reducing the rates of AIDS in his country, in part by recharacterizing the disease as similar to any other threat to the community: "When a lion comes into your village," he said, "you must raise the alarm loudly."
It is time to sound the alarm again. Whereas reported case fatality rates for cholera in the rest of the world are now well below 1%, rates in excess of 5% are still commonly reported in many African countries.1 According to United Nations agencies, the cumulative case fatality rate in the ongoing cholera epidemic in Zimbabwe remained stubbornly above 4.7% through February 12, 2009, by which point 5 months had elapsed since the epidemic began, and more than 73,000 cases and 3500 deaths had been reported (see graph and slide show). The epidemic in Zimbabwe shows no signs of waning and has spread to neighboring South Africa and Zambia, causing thousands of additional cases. Unrelated epidemics in more than a dozen countries in sub-Saharan Africa within the past year have caused nearly 100,000 illnesses and well over 1000 deaths (see map and interactive map within slide show).
|
|
Although it is clear that resources and political will must be mobilized to bring the sanitary and treatment revolutions to sub-Saharan Africa, critical questions remain about cholera prediction, prevention, and response in Africa. We are only beginning to understand the interactive microbial and societal virulence factors that influence the spread of V. cholerae. Recently shed vibrios, for example, appear to be substantially more infectious than those that have adapted to their aquatic environment — a finding that highlights the importance of disruptions in water and sanitation. Rising water temperatures, which lead to plankton blooms, may increase the prevalence of vibrios in the natural environment and the risk of epidemic cholera in areas where drinking water is obtained from untreated surface sources. Vibriophage, on the other hand, may dampen an epidemic and might provide a biologic tool for epidemic control. Inexpensive techniques for household water treatment (including point-of-use chlorination, filtration, and solar disinfection) can prevent cholera and other waterborne diseases but have not been scaled up to reach the hundreds of millions of people who could benefit from them while awaiting access to piped treated water. An oral cholera vaccine is widely marketed, but despite a successful field trial in Mozambique,5 the number of doses, time required to engender protective immunity, short duration of protection, and cost have limited its usefulness in epidemic response and in the control of endemic disease. A less expensive and simpler single-dose formulation of this vaccine is currently in field trials.
In 2005, the reported incidence of cholera in Africa was 95 times that in Asia and 16,600 times that in Latin America. In 2007, the reported rate of death from cholera in Africa was seven times that in Asia; no cholera-related deaths have been reported in Latin America since 2001.1 These preventable cases and deaths result from a lack of essential infrastructure, inadequate health care delivery, and the failure of the global community to muster the political will necessary to extend the benefits of the sanitary and treatment revolutions to all people. The lion is in our human village, and we must do more than sound the alarm.
No potential conflict of interest relevant to this article was reported.
The views presented here are those of the authors and are not necessarily those of the Centers for Disease Control and Prevention.
Source Information
Dr. Mintz is leader of the Diarrheal Diseases Epidemiology Team, Enteric Diseases Epidemiology Branch, Centers for Disease Control and Prevention, Atlanta. Dr. Guerrant is the director of the Center for Global Health at the University of Virginia School of Medicine, Charlottesville.
References
| |||||||||||||||||||||||||||||||||||||
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved. |